TGFB2 and myocardial infarction: However, treatment with the PPAR-δ agonist after MI in vivo might show different effects on wound fibrosis because of different humoral environments, such as elevated TGF-β2, and different origins and characteristics of myofibroblasts from MSCs or adult structural cardiac cells.